Tissue and cell-type analyses show heritability enrichment in neural tissues and neuronal cell types, with the dentate gyrus among the strongest signals.

A strong link was identified between fibromyalgia risk and the HTT gene, and a second variant affecting a receptor that regulates HTT levels points to potential drug targets.

A large multi-ancestry GWAS meta-analysis across 11 cohorts from multiple countries identified 26 independent genetic risk loci for fibromyalgia in about 2.56 million individuals, including 54,629 cases and 2,509,126 controls.

The study utilized a fixed-effects inverse-variance meta-analysis to combine data across cohorts.

Pathways implicated in pain processing and brain function recur across the findings, including CELF4, DRD2, CAMKV, MDGA2, and DCC.

Prioritized causal genes—via literature review and FLAMEs/deCODE analyses—highlight brain-related roles for HTT, DCC, MDGA2, and CELF4, suggesting links to neurodevelopment and pain pathways.

Researchers emphasize fibromyalgia as a biological condition rather than purely psychological, which could reshape clinical approaches and patient experiences.

The strongest association centers on a coding variant in the HTT gene, with carriers having about a 9% higher odds of fibromyalgia (OR ~1.09).

Experts say these genetic insights could improve future diagnosis and treatment, and may intersect with ongoing Huntington's disease drug trials targeting related pathways.

Results reinforce the biological basis of fibromyalgia and suggest genetic overlap with conditions like lower back pain and irritable bowel syndrome, implying shared underlying mechanisms.

The study identifies pathways that could inform future treatments, including potential relevance to Huntington's disease drug research, while noting the condition is not primarily autoimmune.

(no content)